Compare Novavax Inc (NVAX) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Novavax Inc trades at $12.49 (market cap $1.82B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.65 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 92.6× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Vanguard Emerging Markets Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Vanguard Emerging Markets Stock Index Fund ETF for 134 Days on average.
| NVAX | VWO | |
|---|---|---|
Market Cap | $1.82B | $168.50B |
Volume | 6,198,505 | 9,650,999 |
Sector | Health | — |
52-Week High | $12.56 | $61.44 |
52-Week Low | $6.22 | $52.42 |
Typical Hold Time | 59 Days | 134 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
VWO trades at $59.77, down 0.13% on the day, with a bearish technical signal from moving averages and key indicators like ADX signaling selling pressure. Recent news highlights a divergence in performance, with AI-driven strength in Taiwan holdings like TSMC offset by economic weakness in China. The ETF's focus on over 6,000 emerging-market stocks provides diversification but faces concentration risks.
The outlook is cautious due to mixed technicals and regional economic headwinds, particularly in China. Opportunities exist from AI infrastructure growth, but risks include currency volatility and reliance on a few key markets. Investors should weigh the ETF's low expense ratio against emerging-market volatility and slowing growth in major constituents.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
